Oxford Nanopore announced a strategic restructuring that included job reductions and a narrowed product focus while reporting 22% revenue growth for 2025. The company said it will discontinue some platforms, refocus R&D, and redeploy headcount into production and commercial teams to meet rising demand. Management described the actions as simplifying the portfolio and concentrating investment on high‑priority opportunities; the company absorbed restructuring costs of about £22.6 million. The update signals a pivot toward near‑term commercial discipline while balancing longer‑term platform investments in nanopore sequencing.